Based on the Bristol-Myers Squibb Company stock forecast from 14 analysts, the average analyst target price for Bristol-Myers Squibb Company is USD 51.88 over the next 12 months. Bristol-Myers Squibb Company’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Bristol-Myers Squibb Company is Slightly Bearish, which is based on 5 positive signals and 7 negative signals. At the last closing, Bristol-Myers Squibb Company’s stock price was USD 58.23. Bristol-Myers Squibb Company’s stock price has changed by -0.46% over the past week, +11.72% over the past month and +20.11% over the last year.
No recent analyst target price found for Bristol-Myers Squibb Company
No recent average analyst rating found for Bristol-Myers Squibb Company
Company Overview Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey. Address: Route 206 & Province Line Road, Princeton, NJ, United States, 08543 Read Less
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products inc...Read More
Frequently Asked Questions About Bristol-Myers Squibb Company (BMY) Stock
Based on ratings from 14 analysts Bristol-Myers Squibb Company's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 2 buy, 5 sell and 18 hold ratings.
BMY stock's dividend yield is 4.12%.
Our analysis grades BMY stock's dividend yield at C-. This means that BMY stock's dividend yield is above 71% of the stocks in the Drug Manufacturers - General sector in the NYE exchange.
Based on this BMY may be a average dividend stock for its sector.
Based on targets from 14 analysts, the average taret price for BMY is USD 51.88 over the next 12 months. The maximum analyst target price is USD 73 while the minimum anlayst target price is USD 37.
BMY stock's Price/Earning ratio is 12.66.
Our analysis grades BMY stock's Price / Earning ratio at B. This means that BMY stock's Price/Earning ratio is above 14% of the stocks in the Drug Manufacturers - General sector in the NYE exchange.
Based on this BMY may be undervalued for its sector.
The last closing price of BMY's stock was USD 58.23.
The most recent market capitalization for BMY is USD 118.10B.
Based on targets from 14 analysts, the average taret price for BMY is projected at USD 51.88 over the next 12 months.
This means that BMY's stock price may go down by -10.91% over the next 12 months.
We can't find any ETFs which contains Bristol-Myers Squibb Company's stock.
As per our most recent records Bristol-Myers Squibb Company has 34,100 Employees.
Bristol-Myers Squibb Company's registered address is Route 206 & Province Line Road, Princeton, NJ, United States, 08543.
You can get more information about it from Bristol-Myers Squibb Company's website at https://www.bms.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
Poor return on assets
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Bristol-Myers Squibb Company (BMY) Stock
Based on ratings from 14 analysts Bristol-Myers Squibb Company's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 2 buy, 5 sell and 18 hold ratings.
BMY stock's dividend yield is 4.12%.
Our analysis grades BMY stock's dividend yield at C-. This means that BMY stock's dividend yield is above 71% of the stocks in the Drug Manufacturers - General sector in the NYE exchange.
Based on this BMY may be a average dividend stock for its sector.
Based on targets from 14 analysts, the average taret price for BMY is USD 51.88 over the next 12 months. The maximum analyst target price is USD 73 while the minimum anlayst target price is USD 37.
BMY stock's Price/Earning ratio is 12.66.
Our analysis grades BMY stock's Price / Earning ratio at B. This means that BMY stock's Price/Earning ratio is above 14% of the stocks in the Drug Manufacturers - General sector in the NYE exchange.
Based on this BMY may be undervalued for its sector.
The last closing price of BMY's stock was USD 58.23.
The most recent market capitalization for BMY is USD 118.10B.
Based on targets from 14 analysts, the average taret price for BMY is projected at USD 51.88 over the next 12 months.
This means that BMY's stock price may go down by -10.91% over the next 12 months.
We can't find any ETFs which contains Bristol-Myers Squibb Company's stock.
As per our most recent records Bristol-Myers Squibb Company has 34,100 Employees.
Bristol-Myers Squibb Company's registered address is Route 206 & Province Line Road, Princeton, NJ, United States, 08543.
You can get more information about it from Bristol-Myers Squibb Company's website at https://www.bms.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BMY !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
